Atlas Trials

Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease (cGvHD) After Steroid Failure

Clinical trial NCT07643025 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07643025
Sponsor
Dennis Kim
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
cGVHD
Start date
2026-07-01
Primary completion
2029-07-01
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.